Expression of <i>TRIM56</i> gene in SARS-CoV-2 variants and its relationship with progression of COVID-19-Reference-Cited by-同舟云学术

Expression of TRIM56 gene in SARS-CoV-2 variants and its relationship with progression of COVID-19

Published:2023-06 Issue:9 Volume:18 Page:563-574
ISSN:1746-0794
Container-title:Future Virology
language:en
Short-container-title:Future Virology

Author:

Tavakoli Rezvan¹^ORCID,Rahimi Pooneh¹²^ORCID,Hamidi-Fard Mojtaba¹²^ORCID,Eybpoosh Sana³^ORCID,Doroud Delaram⁴^ORCID,Ahmadi Iraj⁵^ORCID,Anvari Enayat⁵^ORCID,Aghasadeghi Mohammadreza¹²^ORCID,Fateh Abolfazl⁶⁷^ORCID

Affiliation:

1. Hepatitis & AIDS Department, Pasteur Institute of Iran, Tehran, Iran

2. Viral Vaccine Research Center, Pasteur Institute of Iran, Tehran, Iran

3. Department of Epidemiology & Biostatistics, Research Centre for Emerging & Reemerging Infectious Diseases, Pasteur Institute of Iran, Tehran, Iran

4. Quality Control Department, Production & Research Complex, Pasteur Institute of Iran, Tehran, Iran

5. Department of Physiology, School of Medicine, Ilam University of Medical Science, Ilam, Iran

6. Department of Mycobacteriology & Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran

7. Microbiology Research Center (MRC), Pasteur Institute of Iran, Tehran, Iran

Abstract

Aim: The present study aimed to determine a correlation between differential TRIM56 expression levels and severe infections of COVID-19 between the Alpha, Delta and Omicron BA.5 variants. Materials & methods: This study was performed on 330 COVID-19 patients, including 142 with severe and 188 with mild infections, as well as 160 healthy controls. The levels of TRIM56 gene expression were determined using a qPCR. Results: TRIM56 gene showed significantly lower mRNA expression in the severe and mild groups compared with healthy individuals. Our finding indicated the high and low reduction of TRIM56 mRNA expression in Delta and Omicron BA.5 variant, respectively. Conclusion: Further research is needed to characterize the impact of TRIM proteins on the severity of COVID-19.

Publisher

Future Medicine Ltd

Subject

Virology

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fvl-2022-0210

Reference57 articles.

1. An Overview of Pathogen Recognition Receptors for Innate Immunity in Dental Pulp

2. A Virological View of Innate Immune Recognition

3. Pharmacological activation of STING blocks SARS-CoV-2 infection

4. Type I and Type III Interferons – Induction, Signaling, Evasion, and Application to Combat COVID-19

5. Side Effects of Interferon-α Therapy